Yun B. Sang
Songnam, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Atezolizumab and bevacizumab plus chemotherapy versus chemotherapy in non-small cell lung cancer after tyrosine kinase inhibitor failure.
Journal: Therapeutic advances in medical oncology
Published: December 04, 2025
Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year.
Journal: Cancer research and treatment
Published: March 04, 2024
Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab.
Journal: Journal of clinical medicine
Published: January 29, 2024
High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma.
Journal: Journal of Cancer
Published: November 30, 2022
High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma.
Journal: Cancers
Published: October 31, 2022
Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification.
Journal: Journal of clinical and translational hepatology
Published: May 06, 2022
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.
Journal: Frontiers in oncology
Published: November 08, 2021
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
Journal: Therapeutic advances in medical oncology
Published: March 14, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026